Regenerative Stromal Cell Therapy in Allogeneic Hematopoietic Stem Cell Transplantation: Current Impact and Future Directions
Jeffery J. Auletta(Nationwide Children's Hospital), Wouter Van’t Hof(Athersys (United States)), Luis A. Solchaga(Case Western Reserve University), Kenneth R. Cooke(Johns Hopkins University), Robert Deans(Rubius Therapeutics (United States))
Cited by 46
Related Papers
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
A biomarker panel for acute graft-versus-host disease
|Blood|2008|404
COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients
|Journal of Infection|2021|248
Biomanufacturing for clinically advanced cell therapies
|Nature Biomedical Engineering|2018|191